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Abstract
Background: A verifiable consequence of the mutator hypothesis is that even low grade
neoplasms would accumulate a large number of mutations that do not influence the tumor
phenotype (clonal mutations). In this study, we have attempted to quantify the number of clonal
mutations in primary human gliomas of astrocytic cell origin. These alterations were identified in
tumor tissue, microscopically confirmed to have over 70% neoplastic cells.
Methods: Random Amplified Polymorphic DNA (RAPD) analysis was performed using a set of
fifteen 10-mer primers of arbitrary but definite sequences in 17 WHO grade II astrocytomas (low
grade diffuse astrocytoma or DA) and 16 WHO grade IV astrocytomas (Glioblastoma Multiforme
or GBM). The RAPD profile of the tumor tissue was compared with that of the leucocyte DNA of
the same patient and alteration(s) scored. A quantitative estimate of the overall genomic changes
in these tumors was obtained by 2 different modes of calculation.
Results: The overall change in the tumors was estimated to be 4.24% in DA and 2.29% in GBM by
one method and 11.96% and 6.03% in DA and GBM respectively by the other. The difference
between high and lower grade tumors was statistically significant by both methods.
Conclusion: This study demonstrates the presence of extensive clonal mutations in gliomas, more
in lower grade. This is consistent with our earlier work demonstrating that technique like RAPD
analysis, unbiased for locus, is able to demonstrate more intra-tumor genetic heterogeneity in
lower grade gliomas compared to higher grade. The results support the mutator hypothesis
proposed by Loeb.
Background
In normal germ-line and somatic cells, DNA synthesis and
cell division are tightly controlled by various genes, which
help in the maintenance of genetic stability. Defect in any
of these genes results in accumulation of mutations in the
cells. Since an overwhelmingly large portion of the
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of mutations in these regions of the genome. If mutations
occur at a critical point in the coding region of gene(s)
involved in the maintenance of cellular control on prolif-
eration, DNA repair and differentiation, it might lead to
development of a cancerous cell.
Loeb [1] proposed the mutator hypothesis, which stated
that cancer cells would accumulate a large number of
mutations without influencing the phenotype of a cell.
These mutations would arise early in tumor development.
In contrast, the persistence of the mutator phenotype
would be unnecessary, if not detrimental, to the clonal
overgrowth during the final stages of tumor progression
[2]. The mutator hypothesis was based on the observa-
tions of numerous mutations in different types of tumors,
which could not be explained by the mutation rates of
normal somatic cells. We felt that determination of the
extent of clonal mutations in different stages of neoplasia
would provide experimental evidence towards verifying
the mutator hypothesis.
A comparison of the DNA fingerprinting pattern of
tumors with constitutional DNA from the same patient
would identify alterations in tumor genomes in a manner
unbiased for locus. Previous reports [3-5] have demon-
strated the utility of multi-locus VNTR probes for this pur-
pose. Our group [6,7] and others [8] have demonstrated
'clonal' genomic changes in the genomes of brain and
lung tumors by RAPD analysis. By 'clonal' changes we
refer to those mutations that do not influence the tumor
phenotype. We have identified alterations in DNA by
RAPD analysis, a DNA fingerprinting method that does
not select for specific genomic locus; therefore, we consid-
ered these changes as 'clonal' mutations. Since most of the
human genome is non-coding and our selection of RAPD
primers was arbitrary, the majority of the bands amplified
by RAPD analysis represent the non-coding regions of the
genome. Such alterations would differ from the changes
identified using locus specific probes or other methods,
typically used to look for alterations in known oncogenes
or tumor suppressor genes. We have shown that RAPD
analysis can demonstrate extensive intra tumor genetic
heterogeneity [7,9]. We had also observed that the extent
of heterogeneity demonstrated by primers that did not
select for loci capable of critically influencing tumor phe-
notype, was more in DA than the GBM [7].
Glial tumors are the commonest primary brain tumors
and second highest cause of mortality by cancer in young
adults (after hematological malignancies). According to
the WHO classification glial tumors of astrocytic origin
are of four grades, ranging from the least aggressive grade
I (pilocytic astrocytomas) to the grade II (low grade dif-
fuse astrocytoma (DA)), the grade III (anaplastic astrocy-
toma (AA)) and the most aggressive grade IV (GBM). Low
grade tumors can recur as higher grades [10].
Several alterations in specific oncogenes and tumor sup-
pressor genes in glial tumors have already been deter-
mined. These include, amongst others, p53 mutations,
EGF receptor gene amplification, changes in the p21 gene,
and consistent alterations in loci on chromosome 10 and
in the 17p13.3 locus [11-13]. These changes as well as
chromosomal alterations and aneuploidy are more fre-
quent in GBM. But the overall extent of clonal changes in
glioma genome has not been reported. Recently, an
inverse correlation between genetic aberrations and
malignancy grade was reported in ependymal tumors
[14]. Moreover, colorectal cancers with a high frequency
of point mutations displayed a comparatively stable kary-
otype [15]. Whether similar is true for tumors of astrocytic
origin is not known.
In this study we tried to determine the extent of mutations
in low and high grade primary human tumors of astro-
cytic origin. Any attempt to quantify the overall changes in
a tumor genome would have its limitations. However, we
have tried to clearly define the assumptions and deline-
ated the limitations as precisely as possible.
Methods
Tumor sample preparation and DNA isolation
This study was approved by the institutional ethics com-
mittee. Tumor and blood samples were obtained from
patients with prior informed consent from each patient.
Surgically resected tumor samples were collected from the
neurosurgery operation theatre of All India Institute of
Medical Sciences, India. All cases were primary tumors
and had received no prior chemo or radio therapy. No
recurrent tumors were taken. Tissue was snap frozen
immediately after surgery and frozen sections cut from the
entire tumor. Every 15th section was stained with toluidine
blue and examined microscopically. Regions of the tumor
having more than 70% neoplastic cells (rest necrosed tis-
sue or vasculature, inseparable from the tumor cells) were
scraped and used for preparation of DNA. Large tumors
were compartmentalized to segments of 50 sections each
[7] and DNA from only one such segment (selected at ran-
dom) was used in the study. Leucocytes of the same
patients were the source of corresponding constitutional
DNA. DNA from both tumor and blood were extracted by
Proteinase K digestion and Phenol:Chloroform extraction
[16].
RAPD analysis
10-mer primers of random but definite sequences of
50–80% GC content were purchased from Genosys,
Texas, USA; and used with varying magnesium chloride
concentrations and annealing temperature (Table 1) forPage 2 of 13
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the forward and reverse primer [17,18]. A set of 15 such
primers was used in this study. A band was amplified
when complementary sequences capable of primer bind-
ing were present in genome on opposite DNA strands
within a PCR amplifiable distance. For each 20 μl PCR
reaction, 100 ng genomic DNA, 50 pM of primer, 0.75 U
of Taq DNA polymerase, 200 μM of dNTP (both from
Genie, Bangalore, India) each and specified concentration
of magnesium chloride were used. After Hot-start, PCR
was done for 33 cycles of 1 min. at 94°C, 1 min. at speci-
fied annealing temperature and 2 min. at 72°C with 1 sec
extension in each cycle in either a MJ Research mini ther-
malcycler (Model No. PTC 150) or Perkin Elmer DNA
Thermocycler (Model No. 480). PCR conditions were set
to obtain a reproducible and distinct banding pattern. The
annealing temperature varied from 22°C to 48°C and
MgCl2 concentration varied from 1.5 mM to 4.5 mM. PCR
products were subjected to 1.5% agarose gel electrophore-
sis in 1× TAE buffer, visualized by ethidium bromide
staining and documented. The model of the thermal
cycler was not changed for a particular primer during the
course of the study. Each RAPD reaction showing altered
bands in tumor was confirmed by at least two independ-
ent experiments.
Scoring
Scoring was done by comparing the RAPD profile of every
tumor with each primer to its paired constitutional DNA
RAPD profile of the same primer [7]. In order to rule out
artifacts caused by efficiency of amplification or sample
loading, only those bands were scored for alterations
where the preceding and succeeding bands had compara-
ble intensities in the tumor and paired normal DNA. A
new band in tumor profile was scored as 'gain', and a
band present in normal DNA but not in tumor DNA, was
scored as 'loss'. Total number of amplified and altered
bands (gain/loss) were counted. To ensure uniformity in
scoring, bands showing increased intensity in tumors
have not been scored even though that may have resulted
in alterations being under reported. RAPD bands in
tumors with intensity significantly lower (≤ 30%) than the
control were scored as loss of band (as some contamina-
tion with normal tissue could not be ruled out). This was
similar to scoring for loss of heterozygosity reported in lit-
erature. Scoring was done by three observers independ-
ently. Any difference was resolved mutually.
The size of different bands in the RAPD analysis was cal-
culated with the help of FotoEclipse System (Fotodyne
Inc, Wisconsin, USA), Collage version 4 Software. The
total length of all the bands amplified as well as the total
length of the altered bands in each RAPD reaction was cal-
culated. Mean percentage alteration of DNA for each
tumor by each primer and in the groups of DA and GBM
were calculated.
Leucocyte DNA as constitutional DNA
Since it was not possible to obtain corresponding normal
brain tissue as a control for tumor DNA, we used blood
DNA of same patient as normal DNA. With the assump-
tion that DNA from any normal tissue will essentially be
the same and would give same profile, we compared the
RAPD profile of leucocyte DNA with buccal mucosal DNA
of same person in 6 volunteers. We also collected leuco-
cytes from individuals at intervals of 4–6 months, up to a
period of 2 years and determined the reproducibility of
the RAPD profile in same individual's DNA over time.
Precautions for reproducibility
One of the concerns regarding data obtained by RAPD
analysis regards reproducibility of data. In this study
Table 1: RAPD primer sequences and PCR conditions
Primer ID Primer Sequence Magnesium Chloride Concentration (mM) Annealing Temperature (°C)
50/09 5' AGAAGCGATG 3' 1.5 28
50/24 5' GTTAGTGGCA 3' 3.0 22
60/39 5' CGCTGTTACC 3' 3.0 28
70/09 5' TGCAGCACCG 3' 3.0 42
70/31 5' GCCCCTCTT G 3' 3.0 36
70/34 5' GGACCGCTAG 3' 3.0 33
70/40 5' CGCAGACCTC 3' 4.5 33
80/03 5' CCATGGCGCC 3' 3.0 48
80/06 5' GCACGGAGGG 3' 4.5 42
80/32 5'GCCCCATGCG 3' 4.5 48
80/35 5' CACCTGCCGC 3' 1.5 45
80/37 5' CGCCAGGAGC 3' 4.5 42
RE-05 5' GCGAATTCCG 3' 3.0 37
RE-06 5' CGGAATTCCG 3' 3.0 37
RE-21 5' GGCTGCAGCG 3' 3.0 45Page 3 of 13
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in experimental results as discussed in our earlier reports
[7,9]. Essentially, only those primers that demonstrated
clear and reproducible RAPD amplification patterns were
used. We took precautions to maintain DNA and primer
quality and also observed the precautions for scoring that
are described earlier in the paper.
Southern Blot analysis for determining the uniqueness of 
the altered band
Five randomly selected altered bands were hybridized to
the RAPD profile of the tumor and control DNA from
which they were derived. This was done to determine
whether an altered band was unique in its corresponding
RAPD profile or whether the alterations were caused by
minor changes in the microsatellite repeat sequences of
any of the other bands in the same sample. After the RAPD
profile of the tumor and corresponding normal DNA was
resolved by agarose gel electrophoresis, it was transferred
to a nylon membrane (Hybond N, Amersham, UK) by
capillary blotting and UV cross-linked to the membrane.
The altered band, which had been previously eluted from
a gel and purified, was labeled by PCR reaction using
P32dCTP (NEN, USA). The labeled probe was extracted
and purified. Hybridizations were carried out in 5× SSC,
0.5% SDS and 5% dextran sulfate at 62°C over night. The
membranes were washed twice with 2× SSC at room tem-
perature, followed by 2 washes in 0.5× SSC at 62°C for 30
minutes each and 2 washes with 0.1× SSC for 2–3 min at
room temperature and auto-radiographed by using X-
omat XK-5 film (from Kodak).
Cloning and sequencing of the altered bands
Five altered bands identified by RAPD analyses were fur-
ther analyzed by cloning, sequencing and homology
search.
Estimation of overall extent of alterations in tumor 
genome
The calculations for determining the extent of genomic
changes in tumors were done by two modalities using cri-
teria, which were mutually exclusive. For both these
modalities we have made certain assumptions. These
assumptions were not complete and carry obvious limita-
tions as stated. However, we believe that these limitations
do not challenge the essential validity of our observation.
Method I
The basic assumption was that the RAPD primer binding
sites were representative of the entire genome in an unbi-
ased manner. Obviously this cannot be true for coding or
critical regulatory sequences but are likely to be represent-
ative of the non-coding regions of the genome, which any
way, form the bulk of the genome. For amplification of a
band in RAPD analysis same primer has to bind to com-
plementary sites on both strands. These sites should be at
a distance suitable for PCR amplification. Because of the
low stringency employed in the technique, RAPD priming
can occur even with 6–8/10 matches in the primer if the
3' end is matched [19]. Hence, a total of 2 such (6–8 base)
matches per haploid genome or 4 matches per diploid
genome is assumed if a band was observed. Another
important assumption was that each band in a RAPD pro-
file actually represents two bands, each amplified from a
haploid genome. We felt this as a justifiable approxima-
tion because: a) PCR products were resolved by 1.5% aga-
rose gels that cannot separate the 2 alleles (that may vary
in size by a few base pairs) as seen in LOH studies. b)
Keeping in mind the frequency of single nucleotide poly-
morphisms (SNPs) and other differences between two
haploid genomes (~1 in 1000 bases), two stretches of
DNA at same locus have a much greater likelihood of
being similar than different. Hence, the minimum infor-
mation that can be derived from one band in a RAPD pro-
file is that of 12–16 bases (6–8 × 2) on primer binding
sites. Any change in the RAPD pattern arose because of
loss or creation of a site suitable for RAPD priming. Since
annealing of a RAPD primer occurs at a low stringency,
and up to 2–4 mismatches can be tolerated under such
conditions, it is likely that a band would not be amplified
if there were a mismatch at the 3' end of any one of the
two primer binding sites. This would be particularly true
for an enzyme like Taq polymerase that does not have
proof reading activity. If a band was visible in RAPD pat-
tern of normal (leucocyte) DNA but not the tumor
(referred as ' loss of band'), it meant mutation at the 3'
end of at least one primer binding site on both the alleles
(that is alteration at 2 sites). The minimum change
required for every new band in a tumor DNA, compared
to its corresponding leucocyte DNA (referred to as 'gain'
in this paper) would be one mutation, which generates a
perfect match, creating a primer binding site. This needs to
occur on only one allele. Since the probability of having
up to 2–4 point mutations in a 10 mer stretch is low, we
have not considered these situations for our calculations.
Our calculations are based on only the need for a perfect
match at the 3' end of the primer for PCR to occur, assum-
ing that a homologous site already exists within an ampli-
fiable distance from the other primer binding site where
the primer can bind in the reverse direction.
A limitation of this approach is that it does not take into
account rearrangements that place primer sites in apposi-
tion or distance them beyond the limit of RAPD amplifi-
cation. Also gross chromosomal alterations not affecting
closely located primer binding sites will not be reflected.
Similarly, amplifications resulting in increased intensity
of a band are not reflected in these calculations. However,
the extent of the error would be similar in high and low
grade tumors resulting a conservative estimate of changes.Page 4 of 13
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culated the extent of mutations in the following way:
a) Number of amplified bands × 4 = the number of rele-
vant 3' ends (as the same primer acts both as forward and
reverse primer and there are two alleles). These are the
total number of bases under consideration.
b) Number of lost bands × 2 = mutations complementary
to the 3' ends of the primer (this is because while a single
mutation altering the base complementary to the 3' ends
of a primer will prevent PCR amplification from one hap-
loid genome, a homozygous change with mutations
occurring in both the alleles is needed for the absence of a
band).
c) Appearance of a new band corresponds to, at least, a
single change which creates a perfect match with the 3'
end of the primer within an amplifiable distance of a pre-
existing match i.e. one additional band in the tumor = 1
mutation. Again, it was assumed that a homologous site
for primer binding already exists and the single mutation
generates only one binding site complementary to the 3'
end of the primer.
The values for every leucocyte/tumor pair for each primer
were calculated separately.
Method II
In the previous method we had only considered mutation
at 3' end of primer binding site as a relevant reason for
observing loss/creation of a new band. No role of
genomic rearrangements, large losses etc. were consid-
ered. In this method, we calculated the extent of change
taking the other extreme assumption that all changes are
due to rearrangements or losses and none were due to
mutations at the bases annealing to the 3'end of the
primer. The size of each RAPD amplified bands (33 sam-
ple pairs, each with 15 different primers) was determined
(as mentioned above). The length of DNA amplified by
each primer from each patient's leucocyte DNA was indi-
vidually determined and added up to estimate the total
length of DNA amplified by all the primers for each
tumor. The length of each altered fragment (lost/gained)
was determined and added up to estimate the total length
of the DNA fragments altered in a tumor. Mean percent-
age alteration in each tumor by each primer and in DA
and GBM were calculated.
A limitation by this method is that loss/gain of a larger
band on the RAPD profile may not necessarily represent a
larger genomic change than in case of a smaller band.
However, this limitation would be true for both high and
low grade tumors.
The basic difference between both the methods is that
while the first method considers only those bases, which
bind the primer, the second method considers only the
region, which gets amplified by the PCR reaction. It is also
assumed (for both the methods) that bands observed on
RAPD are essentially distinct from each other. This is
based on experiments (discussed below), where in a
number of different tumor-primer combinations, an
altered band was hybridized to the same RAPD profile,
did not hybridize to any other band.
Statistics
Two tailed t test was used to compare extent of aberrations
in DA and GBM by both the methods.
Results
The PCR amplified bands varied between 3 Kb to 400 bp
in size, the majority of bands were less than 1 Kb size (Fig-
ure 1). When the RAPD profile of normal and tumor DNA
was compared, differences were observed within a
number of blood-tumor pairs. This is similar to what we
had reported earlier [6,7].
Leucocyte DNA was taken as a representative of the nor-
mal DNA. The stability of RAPD profile for each primer
was indicated by identical RAPD pattern obtained from
DNA extracted from buccal scraping and the peripheral
blood leucocyte in healthy volunteers (Figure 2). Also the
RAPD profile was stable when leucocyte DNA was
obtained from the same individual on intervals of 4–6
months over periods of up to two years (data not shown).
The RAPD results are summarized in Tables 2, 3, 4, 5.
Thirty two tumors (out of 33) showed genetic altera-
tion(s) when studied with this panel of 15 RAPD primers.
These included loss of band/s, gain of band/s, gross
change in intensity of bands or any combination of them.
Approximately half of these alterations were loss of a band
in the tumor, which is present in paired constitutional
DNA of same patient. Tumors of same histological grade
showed different degrees of genetic alteration (e.g. tumor
No. 137 vs. 194; tumor No. 154 vs. 159); also some prim-
ers were more efficient in identifying changes (primer No.
50/09, 80/32) than others (primer No. 70/31, 80/37). In
some cases extensive alterations were demonstrated by
one primer but not by others (eg. tumor No. 137, primer
No. 50/09 and 60/39).
Five altered bands (80/35/127B, RE06/125B, 80/35/
195T, RE05/195B and 70/09/173T) chosen randomly
were tested for homology to other bands in the RAPD pro-
files (both tumor and corresponding normal DNA) from
which they were amplified. Southern hybridization
revealed that these altered bands did not hybridize with
any other band in that RAPD profile. This indicated that Page 5 of 13
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profile or were not result of minor changes in microsatel-
lite repeat sequences in other amplified band. A represent-
ative experiment is shown in Figure 3.
These altered bands were further confirmed for their
uniqueness by cloning and sequencing. They were cloned
in either pGEMT, pGEMT-Easy, pBlueScript or pUC II vec-
tors. Cloned fragments were further analyzed by Southern
hybridization with the corresponding RAPD eluted bands
(accession numbers AF264057, AF264058, AF264059,
AF264060 and AF264061). Unlike the results in AP-PCR
[20,21] where the altered bands were resolved by polyacr-
ylamide gel electrophoresis, no microsatellite repeats were
observed in any of these cloned fragments. However, the
nature of the altered fragments suggested that the
sequences preponderantly were of regions likely to be
involved in recombination. One fragment had homology
with retroposon HERV-K [22] and another to L1 repetitive
element and Chi-core sequences. These are sequences
present in the normal human genome as identified by
BLAST search. These changes are not common among
tumors. Nor are they part of coding sequences. Hence they
indicate alterations in tumor DNA that are not selected for
the locus. The details of the characterized altered frag-
ments are as follows:
Comparison of the normal RAPD profiles obtained from DNA extracted from buccal scraping and the peripheral bl od leucocytes f a healthy volunteer with different prim-ersFigur  2
Comparison of the normal RAPD profiles obtained from 
DNA extracted from buccal scraping and the peripheral 
blood leucocytes of a healthy volunteer with different prim-
ers. The primers number is indicated on the top of the figure. 
B and L indicate buccal mucosal and leucocyte DNA respec-
tively.
70-09  RE-05
L    BL   B 
RAPD patterns of different tumors compared to their corresponding normal DNAFigure 1
RAPD patterns of different tumors compared to their corresponding normal DNA. Leucocytic DNA RAPD profile is marked 
as B and tumor DNA by T. Grade II astrocytoma is indicated as DA and Glioblastoma multiforme is indicated as GBM. Arrow 
indicates an altered band. From left to right, upper panel: 80/32 with 154; 80/03 with 278; 60/39 with 195; 70/09 with 195; 50/
09 with 172; lower panel: RE21 with 173; RE05 with 195; primer 70/09 with tumor 175; RE06 with 154; RE21 with 175.
DA
B  T
GBM
B  T
GBM
B  T
GBM
B  T
DA
B  T
DA
B  T
DA
B  T
DA
B  T
GBM
B  T
GBM
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AF264058) showed homology with parts of retroposons
of human endogenous retrovirus origin (accession nos.
X07417, X07418 and X07419). Retroposons are repeated
sequences and are widely distributed in the human
genome. BLAST homology also showed several stretches
of various lengths of this altered sequence interspersed
throughout the human genome (accession nos.
AV373514, Z73358, AB000381, AC000387, U91326,
D84394, Z69710, Z69710, AC002992, Z11740, Z82196
and Z83841).
ii) Altered fragment (RE06/125B) (accession no.
AF264061) showed partial homology to L1 repetitive
sequence. L1 sequences are highly repetitive interspersed
sequence, an estimated 100,000 L1 elements are present
in the entire human genome. These sequences comprise
as much as 17% of the human genome by weight (Smit
AFA, 1996, Curr.Opin. Genet. Devel., 6, 743–48).
iii) Altered fragment (80/35/195T) (accession no.
AF264060) On homology search, the complete stretch
has no homology with sequences in the public domain
Table 3: Alterations in Glioblastoma multiforme (GBM) calculated by method I
Tumor No. Number of altered bands/total bands amplified Net change % change of bands in different tumors
115 L7G9/137 23/548 4.19
123 L1G2/104 4/416 0.96
125 L4G0/108 8/432 1.85
127 L3G0/141 6/564 1.06
129 L4G5/166 13/664 1.96
131 L0G0/179 0/706 0
154 L10G7/148 27/592 4.56
158 L5G2/181 12/724 1.65
159 L1G0/166 2/664 0.30
173 L3G1/133 7/532 1.31
174 L9G5/115 23/460 5
188 L4G2/141 10/564 1.77
238 L7G8/174 22/696 3.16
241 L7G9/201 23/804 2.86
282 L5G3/91 13/364 3.57
287 L2G9/137 13/548 2.37
The number of lost/gained bands are indicated by L/G, while the total number of bands amplified in the corresponding normal DNA is given as the 
denominator.
Table 2: Alterations in Low grade diffuse astrocytomas (DA) calculated by method I
Tumor No. Number of altered bands/total 
bands amplified
Net change % change of bands in different 
tumors
108 L10G4/204 24/816 2.94
132 L6G5/101 17/404 4.21
137 L16G16/172 48/688 6.98
150 L4G4/100 12/400 3
172 L4G3/71 11/284 3.88
175 L9G18/121 36/484 7.44
194 L2G0/94 4/376 1.06
195 L20G12/140 52/560 9.28
235 L2G5/211 9/844 1.06
244 L0G5/188 5/752 0.66
245 L3G8/191 14/764 1.83
277 L8G11/138 27/552 4.89
278 L8G8/76 24/304 7.89
279 L7G3/139 17/556 3.06
280 L10G7/129 27/516 5.23
284 L4G4/136 12/544 2.21
285 L9G16/133 34/532 6.39
The number of lost/gained bands are indicated by L/G, while the total number of bands amplified in the corresponding normal DNA is given as the 
denominator.Page 7 of 13
(page number not for citation purposes)
BMC Cancer 2007, 7:190 http://www.biomedcentral.com/1471-2407/7/190database. However, it has 6 nucleotides of the Chi core
octanucleotide (GCTGGTGG) sequence of E.coli. Chi-
core octanucleotide sequence is present at the DNA break
points in human tumors. Chi core influences the proba-
bility of the nearby rearrangement or it alters the regula-
tion of oncogene transcripts once rearrangement occurs
(Krowczynska et al., 1990, Nucleic Acids Res., 18, 1821).
Many such Chi homology sequences repeated in the
human genome have been used for DNA fingerprinting
(Ehtesham et al., 1990, Ind. J. Biochem. and Biophysics.
27; 275–279).
iv) Altered fragment (RE05/195B) (accession no.
AF264059) shows no homology in the human genome
sequence in the public domain data base. However it is an
AT rich sequence and AT rich sequences are reported to be
prone to rearrangement by recombination.
v) Altered fragment (70/09/173T) (accession no.
AF264057) shows no homology in the human genome
sequences in the public domain till date. This sequence
also showed an AT rich sequence.
Table 5: Alterations in Glioblastoma multiforme (GBM)calculated by method II
Tumor No. Total change in tumor DNA 
(kb)
Total Length of Tumor DNA 
(Kb) studied
% alteration of DNA in different 
tumors
115 17.5 119.2 14.3
123 3.6 112.6 3.2
125 4 103.9 3.8
127 3.4 100.8 3.4
129 6.3 134.9 4.7
131 0 145.6 0
154 12.8 126 10.1
158 6.5 167.9 3.8
159 2 138.2 1.4
173 2.2 114.7 2
174 11 97.4 11.3
188 8 131.6 6
238 12.8 174 7.3
241 9.6 185.6 5.2
282 7.3 88.4 8.2
287 3.6 141.2 2.5
Mean percentage alteration in each tumor by each primer was calculated.
Table 4: Alterations in Low grade diffuse astrocytomas (DA) calculated by method II
Tumor No. Total Length of Tumor DNA 
(Kb) studied
Total Length of Change in tumor 
DNA (kb)
% alteration of DNA in 
different tumors
108 116.4 8 6.9
132 90.3 10 11.1
137 123.3 40.2 32.6
150 100.2 4.3 4.3
172 106.6 16.1 15.1
175 123.3 24 19.5
194 104.4 2.6 2.5
195 123 26.3 21.4
235 201.8 9.1 4.5
244 174.3 3.2 1.9
245 202.1 5.3 2.6
277 139.5 13.8 9.9
278 117.1 23.2 19.9
279 168.6 8.1 4.8
280 175.5 16.8 9.6
284 161.5 9.3 5.7
285 125.1 22.3 17.8
Mean percentage alteration in each tumor by each primer was calculatedPage 8 of 13
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The changes observed in Method I are listed in tables 2
(for DA) and 3 (for GBM). For every tumor-primer com-
bination, the number of lost/gained bands are indicated
by L/G, while the total number of bands amplified in the
corresponding normal DNA is given as the denominator.
The number of alterations (3' ends mutated) = Number of
lost bands × 2 + number of gained bands × 1.
The total number of 3' ends studied is = total number of
bands amplified in normal DNA × 4.
The extent of alterations varied from 0.66% to 9.28% in
DA, with a mean value of 4.24 ± 2.62 (standard deviation
or SD). In GBM it varied from 0% to 5%, the mean value
2.29 ± 1.49 (SD). The alterations were more in DA and
statistically significant (two tailed p = 0.014).
Calculations of Genomic Change based on Method II
The results are summarized in table 4 (for DA) and 5 (for
GBM).
The ranges of alterations in DA and GBM were 2.3% to
27.8% and 0% to 20.2% respectively. Only one tumor
(No. 131) showed no genetic change. The mean percent-
age alteration in DA was 11.96 ± 7.44 (SD) and in GBM
was 6.03 ± 5.24 (SD) (Tables 4 and 5). Changes in DA was
significantly higher than in GBM (two tailed p = 0.013).
Discussion
There is considerable debate over the role of genomic
instability as a cause or consequence of tumorigenesis. By
the time a tumor is clinically manifest, it has survived a
checkered history of multiple rounds of cell division, cell
death, clonal expansion and selective growth of some sur-
viving clones. The altered nature of the tumor cells, and
indirectly, the natural history of the tumor would be
reflected in the magnitude of the overall genetic changes
in a tumor. In this work RAPD-PCR of tumors and its
comparison with the normal DNA has been used as a
measure of genomic instability.
Genomic instability in the form of chromosome instabil-
ity, aneuploidy, LOH, microsatellite repeat alterations are
seen in almost all types of neoplastic and preneoplastic
cells. All these mutations have different implications in
the tumor development and progression. However the
cause of genomic instability is still debated. Some authors
find aneuploidy as the primary cause of the genomic
instability in the tumors [23,24]. Ninomiya et al [25] have
found chromosomal instability and LOH to play role in
the development of lung cancer. Goel et al [26] have char-
acterized the role of chromosomal and microsatellite
instability in the progression of colon cancer. In other sys-
tems, if one restricts to microsatellite repeat alterations,
there has been some evidence linking genomic instability
to tumor progression [27,28]. Microsatellite instability
was found to be associated with aggressive colorectal car-
cinoma [29] and ovarian carcinoma [30]. However in a
broader sense, the association of generalized genomic
instability with tumor progression would be somewhat in
contradiction with the mutator hypothesis, in which the
mutations are phenotypically neutral with no direct role
in the progression of the tumors. A mutator phenotype
might be a liability to an aggressive rapidly dividing clone
arising during tumor progression as extensive mutations
might adversely affect the growth properties of these cells
[2]. This apparent contradiction can be resolved if it is
kept in mind that the assays for genomic instability meas-
ure different phenomena, with varying biological implica-
tions. For example, in colorectal tumors increased
frequency of point mutations is associated with a stable
karyotype [15], which is less likely to be associated with
progression.
There have been several attempts to estimate the extent of
alterations in tumor genomes. Ionov et al [20] used radi-
oactive Arbitrarily Primed PCR (AP-PCR) and PAGE to
study genomic mutations in colorectal carcinoma, docu-
menting and characterizing bands altered in tumors. AP-
PCR is similar to RAPD except the primers used are longer.
Representative Southern hybridization experiment for d tecting homology of the altered ba d with other bands in the RAPD profi eFigure 3
Representative Southern hybridization experiment for 
detecting homology of the altered band with other bands in 
the RAPD profile. When RAPD analysis was performed with 
tumor no 195 and corresponding normal DNA with primer 
RE 05, loss of a normal band in tumor tissue was detected. 
Probe made by labeling this band (eluted from the gel in a 
previous experiment), did not hybridize to any other band in 
either tumor or normal DNA.
B      T B     TPage 9 of 13
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tion for band sizes up to 1 kb and observed that altered
bands in tumors were identical to the closest normal band
except for deletions in repeats like poly A, dinucleotides
like CT and CA or trinucleotide repeats. Their estimation
of changes in the genome was about 1.3–1.5 per 105 bases
in cancer tissue. This is very different from what we see. In
our study, most of the altered bands do not have any
homology with any other bands in the same RAPD profile
as confirmed by Southern hybridization of the altered
bands to the RAPD profile (Figure 3).
Jackson and Loeb [31] estimated ~100,000 genome wide
alterations in cancers in the form of base substitutions,
deletions, chromosomal translocations, and gene amplifi-
cations, and these mutations are found to accumulate as
tumors progress. They proposed that the genomic insta-
bility caused by these alterations result from a mutator
phenotype, which occurs early during tumor develop-
ment and predisposes the tumor cell to the accumulation
of further mutations. They [32] emphasized the impor-
tance of considering different types of alterations in
genome of malignant cells, like aneuploidy, transloca-
tions and amplifications along with those detected by
molecular methods like analysis of loss of heterozygosity,
microsatellite instability etc. Similarly Kerangueven et al
[33] have found extensive genetic diversity from a genome
wide scan for loss of heterozygosity. Accumulation of sim-
ple random point mutations can lead to carcinogenesis
[34]. To predict the relative contribution of mutator
mutants in cancer, Beckman and Loeb [35] have devel-
oped a mathematical model that quantitatively deter-
mines the efficiency of carcinogenesis with and without
mutator mutations. Recently Beilas et al [36] have meas-
ured random mutations in normal and neoplastic human
tissues and have found an elevation in random mutations
of at least two orders of magnitude in neoplastic tissues.
There are studies using inter-simple sequence repeat PCR
(ISSR-PCR), a DNA fingerprinting method to identify
genomic instability in the tumors. Basik et al [37] found
that the extent of alterations detected in colorectal cancer
using ISSR-PCR had no relationship with the tumor stage
at diagnosis and microsatellite instability, though it was
associated with loss of heterozygosity. The number of
genomic alterations in colorectal cancer cells was more
than expected and mean number of alterations per cell
was ~11,000 [38]. The lack of association of this phenom-
enon with tumor grade and observation of similar
number of events in colonic polyps and colon carcinoma
supports the theory that genomic instability occurring
early during malignant change. Stoler et al [39] using
ISSR-PCR found genomic instability in invasive breast car-
cinoma. The mean instability index was 3.08%, which
was similar to the mean value observed in colorectal and
thyroid carcinoma studied by the same group. Using ISSR-
PCR Rai et al [40] showed genome wide instability with
the mean instability index of 12% in chewing-tobacco
associated oral cancer. However, ISSR-PCR measures only
a specific type of regions in genome, between two defined
repeats located end to end within a certain distance from
each other. The RAPD analysis used in our study targets
genomic loci of a different nature and we estimate that the
number of overall alterations in tumor genome seems to
be greater than earlier appreciated. While the estimated
number of alterations in our study is different from that
observed using ISSR-PCR, the observation of absence of
increased genomic alteration by Basik et al [37] in higher
grade tumors is similar to our finding. Both ISSR-PCR and
RAPD-PCR are techniques for measuring genomic
changes that are likely to be phenotypically neutral.
Tomlinson et al [41] proposed that normal mutation rate
is sufficient to explain a large number of mutations in
tumors if the number of cell divisions during normal
development is taken into account. We were not able to
study normal brain tissue as control, and used normal leu-
cocyte DNA. We checked the stability of the RAPD analy-
sis by comparing the RAPD profile of buccal mucosal
DNA with the leucocyte DNA from the same volunteer.
Also the leucocyte DNA from individuals was obtained in
intervals of 4–6 months over a period of two years, and
RAPD profile of each sample were identical for the same
person. The identical RAPD profile from buccal mucosal
and leucocyte DNA, along with stability of leucocyte DNA
profile over a period of 2 years, during which there would
be a lot of cellular turnover, indicates that the alterations
described in this study do not represent alterations accom-
panying cell division that might occur during normal
development. These results, along with the universal
forensic practice of taking the DNA fingerprinting profile
of leucocyte DNA as representative of normal DNA for
comparison with DNA of diverse tissue origins, body flu-
ids etc. justifies the use of blood as constitutional DNA in
our study.
Most of the published work till date on the extent of muta-
tions in tumors is on colon carcinogenesis. Our study is
on primary human glial tumors of astrocytic origin and
we have taken DA and GBM as representative of low and
high grade tumors of same cell origin. The mean estimate
of alterations observed in tumor genomes varied between
4.42% in DA and 2.29% in GBM by method I and 11.96%
(DA) and 6.03% (GBM) by method II. The difference
between DA and GBM by both the methods was statisti-
cally significant. The increased extent of alterations occur-
ring in tumors of a lower grade differs from the results
obtained by some studies using AP-PCR [29,30]. Both
RAPD and AP-PCR are basically similar techniques, rely-
ing on a single primer to identify sites in both directionsPage 10 of 13
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ever, there are basic differences in the methods employed
by us and by the other researchers, which seems to have
resulted in an altogether different form of clonal muta-
tions identified in our study. In previous studies using AP-
PCR followed by PAGE, the altered bands (as determined
by sequencing) were found to differ from the closest nor-
mal counterpart only by small runs of simple repeat
sequences. In our case the altered bands did not have any
similarity with the normal bands on the RAPD profile.
Five of the altered bands, characterized in detail, did not
hybridize with any other band in the RAPD profile of
either tumor or paired normal DNA (Figure 3). Sequenc-
ing showed no microsatellite repeats in these altered frag-
ments. These unique sequences were homologous to
some recombinogenic sequences like HERV-K [22], L1
repeat sequence and Chi-core sequences (manuscript in
preparation) and had the potential to mediate alterations
in the genome by repeat mediated recombination and
other mechanisms. Thus the changes identified by us are
not due to microsatellite repeats being deleted from or
added to the nearest normal band. The different nature of
changes identified by us could be because of use of agar-
ose gel to separate the PCR amplified bands. Agarose gel
has a lower resolution range than PAGE, and while they
have been extensively used in RAPD analysis, they do not
resolve changes of few base pairs caused by microsatellite
expansion and contraction. Hence, the changes detected
by us were qualitatively different from the earlier studies.
The size of bands studied by us is also different, up to
2.5–3 kb as opposed to much smaller bands studied by
other groups. We have also used 10 mer primers, which
would be expected to prime more promiscuously than
longer primers used by others.
Our observation of a higher number of genetic changes in
tumors of lower grade could be a consequence of an
increased mutation rate in early tumorigenesis due to
acquisition of a mutator phenotype. It is assumed that in
absence of selection pressure the number of mutations
would be more. However, the mutator phenotype would
be at a disadvantage to a more aggressive rapidly growing
clone [2] as would be expected in a GBM, especially in a
primary GBM. The higher number of mutations could
also be a reflection of the longer time taken by a low grade
tumor to clinically manifest, compared to a higher grade
tumor. Mutations could accumulate in non-dividing cells
[42], thus making tumors with low proliferation indices
e.g., grade II (DA) tumors accumulating more mutations
than grade IV (GBM) tumors. Another factor could be the
higher rate of apoptosis in low grade tumors, which
would lead to cell populations in DA accumulating more
clonal mutations, both as a function of time as well of cell
divisions, before the tumor is manifested clinically.
We have earlier demonstrated that RAPD analysis reveals
increased intra-tumor genetic heterogeneity in DA com-
pared to GBM [7]. When DNA was independently
extracted from consecutive segments of 50 sections each,
more differences between the segments of the same tumor
were detected in DA compared to GBM. This result was
also in concordance with the acquisition of a mutator
phenotype early in tumorigenesis, leading to the co-exist-
ence of progeny cells with different DNA fingerprinting
patterns, especially in low-grade tumors. It would be
expected that heterogeneity might give the impression of
increased change in a large tumor. In order to exclude
such a possibility, we used DNA made from only one seg-
ment of 50 consecutive sections in each tumor used in our
study. Similarly another study by our group [43] has
observed very significantly higher level of loss of heterozy-
gosity (LOH) in the hMLH1 gene locus in DA compared
to GBM using microsatellite markers, correlating with our
earlier result which showed more intra tumor genetic het-
erogeneity in low grade gliomas.
The uniqueness of our study lies in the high estimated
number of mutations. Also the estimated number of
clonal mutations is greater than earlier reported, and not
just restricted to microsatellite repeat sequences length.
The extent of such changes is more in the low grade tumor
type (DA) than in high grade GBM. Our evidence is in
favor of dissociation of the dynamics of clonal mutations
that are phenotypically neutral from those genetic
changes leading to a phenotype with growth advantage.
This is in concordance with the applicability of the muta-
tor hypothesis. A further study comparing primary and
secondary GBM would provide more evidence for its
applicability in glial tumors. Similar approaches can also
be used to study the role of mutations that do not have
phenotypic consequences in other tumor types as well.
Conclusion
In this study, using locus non selective RAPD fingerprint-
ing method, we studied the genomic instability in the
astrocytic tumors of WHO grade II (DA) and grade IV
(GBM), using leucocyte DNA of the same patient as con-
trol. The alterations detected were non coding sequences,
not common among tumors, and indicate that they are
not selected for specific locus. The quantitative estimation
of the overall genomic changes detected in these tumors
was done by two mutually exclusive modes of calculation,
yielding similar results. The results demonstrate the pres-
ence of extensive clonal mutations in gliomas, more so in
the grade II astrocytomas. This is in line with the mutator
hypothesis – that, those mutations/genetic alterations
that do not have a significant phenotypic correlation are
likely to be more frequent in low grade tumors. This is in
consistent with our earlier work demonstrating that tech-
nique like RAPD fingerprinting analysis is able to demon-Page 11 of 13
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BMC Cancer 2007, 7:190 http://www.biomedcentral.com/1471-2407/7/190strate extensive intra-tumor genetic heterogeneity in all
grades of gliomas, more so in lower grade as compared to
higher grade. Our results showed the acquisition of a
mutator phenotype early in tumorigenesis and support
the mutator hypothesis proposed by Loeb.
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